Regulation of gene expression in ovarian cancer cells by luteinizing hormone receptor expression and activation

BackgroundSince a substantial percentage of ovarian cancers express gonadotropin receptors and are responsive to the relatively high concentrations of pituitary gonadotropins during the postmenopausal years, it has been suggested that receptor activation may contribute to the etiology and/or progression of the neoplasm. The goal of the present study was to develop a cell model to determine the impact of luteinizing hormone (LH) receptor (LHR) expression and LH-mediated LHR activation on gene expression and thus obtain insights into the mechanism of gonadotropin action on ovarian surface epithelial (OSE) carcinoma cells.MethodsThe human ovarian cancer cell line, SKOV-3, was stably transfected to express functional LHR and incubated with LH for various periods of time (0-20 hours). Transcriptomic profiling was performed on these cells to identify LHR expression/activation-dependent changes in gene expression levels and pathways by microarray and qRT-PCR analyses.ResultsThrough comparative analysis on the LHR-transfected SKOV-3 cells exposed to LH, we observed the differential expression of 1,783 genes in response to LH treatment, among which five significant families were enriched, including those of growth factors, translation regulators, transporters, G-protein coupled receptors, and ligand-dependent nuclear receptors. The most highly induced early and intermediate responses were found to occupy a network impacting transcriptional regulation, cell growth, apoptosis, and multiple signaling transductions, giving indications of LH-induced apoptosis and cell growth inhibition through the significant changes in, for example, tumor necrosis factor, Jun and many others, supportive of the observed cell growth reduction in in vitro assays. However, other observations, e.g. the substantial up-regulation of the genes encoding the endothelin-1 subtype A receptor, stromal cell-derived factor 1, and insulin-like growth factor II, all of which are potential therapeutic targets, may reflect a positive mediation of ovarian cancer growth.ConclusionOverall, the present study elucidates the extensive transcriptomic changes of ovarian cancer cells in response to LH receptor activation, which provides a comprehensive and objective assessment for determining new cancer therapies and potential serum markers, of which over 100 are suggested.

[1]  M. Houweling,et al.  Luteinizing hormone inhibits Fas-induced apoptosis in ovarian surface epithelial cell lines. , 2006, The Journal of endocrinology.

[2]  I. Huhtaniemi.  Are gonadotrophins tumorigenic—A critical review of clinical and experimental data , 2010, Molecular and Cellular Endocrinology.

[3]  E. Dennis,et al.  Handbook of cell signaling , 2004 .

[4]  L. Muller,et al.  Small interfering RNA molecules targeting endothelin-converting enzyme-1 inhibit endothelin-1 synthesis and the invasive phenotype of ovarian carcinoma cells. , 2008, Cancer research.

[5]  Edgar Rivedal,et al.  Downregulation of gap junctions in cancer cells. , 2006, Critical reviews in oncogenesis.

[6]  M. Skinner,et al.  Expression and actions of both the follicle stimulating hormone receptor and the luteinizing hormone receptor in normal ovarian surface epithelium and ovarian cancer , 2001, Molecular and Cellular Endocrinology.

[7]  T. Kohonen.  Self-Organized Formation of Correct Feature Maps , 1982 .

[8]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[9]  A. M. Shapiro,et al.  Combination therapy with low dose sirolimus and tacrolimus is synergistic in preventing spontaneous and recurrent autoimmune diabetes in non-obese diabetic mice , 2002, Diabetologia.

[10]  I. Konishi,et al.  LH/hCG action and development of ovarian cancer—A short review on biological and clinical/epidemiological aspects , 2007, Molecular and Cellular Endocrinology.

[11]  D. Puett,et al.  Luteinizing Hormone–Induced Up-Regulation of ErbB-2 Is Insufficient Stimulant of Growth and Invasion in Ovarian Cancer Cells , 2008, Molecular Cancer Research.

[12]  S. Lowry,et al.  Incessant ovulation and ovarian cancer , 1991, The Lancet.

[13]  J. Barrett,et al.  Gap junction function and cancer. , 1993, Cancer research.

[14]  Teuvo Kohonen,et al.  Self-organized formation of topologically correct feature maps , 2004, Biological Cybernetics.

[15]  P. Leung,et al.  Gonadotropins induce tumor cell migration and invasion by increasing cyclooxygenases expression and prostaglandin E(2) production in human ovarian cancer cells. , 2010, Endocrinology.

[16]  C. Manetopoulos,et al.  The Notch pathway in cancer: differentiation gone awry. , 2005, European journal of cancer.

[17]  P. Leung,et al.  Endocrine signaling in ovarian surface epithelium and cancer. , 2007, Human reproduction update.

[18]  M. Kuo,et al.  Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-kappaB pathway by lysophosphatidic acid, an ovarian cancer-activating factor. , 2004, Carcinogenesis.

[19]  A. Whittemore,et al.  Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. , 1992, American journal of epidemiology.

[20]  T. Kohonen.  Self-organized formation of topographically correct feature maps , 1982 .

[21]  F. Spinella,et al.  The importance of endothelin axis in initiation, progression, and therapy of ovarian cancer. , 2010, American journal of physiology. Regulatory, integrative and comparative physiology.

[22]  P. Leung,et al.  Gonadotropins and ovarian cancer. , 2007, Endocrine reviews.

[23]  R. Gentz,et al.  An antagonist decoy receptor and a death domain-containing receptor for TRAIL. , 1997, Science.

[24]  R. Jensen,et al.  Do sex steroids exert sex-specific and/or opposite effects on gene expression in lacrimal and meibomian glands? , 2009, Molecular vision.

[25]  G. Watkins,et al.  Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer , 2005, Breast Cancer Research.

[26]  P. Leung,et al.  Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells. , 2006, Cancer research.

[27]  M. Wierman.  Sex steroid effects at target tissues: mechanisms of action. , 2007, Advances in physiology education.

[28]  Wen-Chi Chou,et al.  An integrated transcriptomic and computational analysis for biomarker identification in gastric cancer , 2010, Nucleic acids research.

[29]  I. Holen,et al.  Role of osteoprotegerin (OPG) in cancer. , 2006, Clinical science.

[30]  C. Thompson,et al.  The central effectors of cell death in the immune system. , 1999, Annual review of immunology.

[31]  Cody Schrank,et al.  American Cancer Society , 2005 .

[32]  Carney,et al.  BRCA 1 and 2--A Genetic Link to Familial Breast and Ovarian Cancer. , 1997, Medscape women's health.

[33]  J. Richards,et al.  The ovary: basic biology and clinical implications. , 2010, The Journal of clinical investigation.

[34]  J. de Vos,et al.  LH/hCGR gene expression in human cumulus cells is linked to the expression of the extracellular matrix modifying gene TNFAIP6 and to serum estradiol levels on day of hCG administration. , 2009, Human reproduction.

[35]  J. Russo,et al.  Human chorionic gonadotropin (hCG) and prevention of breast cancer , 2007, Molecular and Cellular Endocrinology.

[36]  P. Leung,et al.  Intracellular calcium mobilization in response to the activation of human wild-type and chimeric gonadotropin receptors. , 2002, Endocrinology.

[37]  E. Vellenga,et al.  Regulation of spontaneous and TNF/IFN‐induced IL‐6 expression in two human ovarian‐carcinoma cell lines , 1999, International journal of cancer.

[38]  R. Ravi,et al.  Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II. , 2002, Cancer research.

[39]  L. Rosanò,et al.  The endothelin axis in cancer. , 2008, The international journal of biochemistry & cell biology.

[40]  K. Stoeber,et al.  The cell cycle and cancer , 2012, The Journal of pathology.

[41]  Freimann Sarit,et al.  Ovarian transcriptomes as a tool for a global approach of genes modulated by gonadotropic hormones in human ovarian granulosa cells , 2005, Endocrine.

[42]  Ying Xu,et al.  Computational prediction of human proteins that can be secreted into the bloodstream , 2008, Bioinform..

[43]  M. Conti,et al.  The cAMP-Specific Phosphodiesterases: A Class of Diverse Enzymes that Define the Properties and Localization of cAMP Signals , 2010 .

[44]  S. Kjaer,et al.  Infertility, fertility drugs, and invasive ovarian cancer: a case-control study. , 1997, Fertility and sterility.

[45]  R. Johnson,et al.  c‐Jun regulates cell cycle progression and apoptosis by distinct mechanisms , 1999, The EMBO journal.

[46]  J. Thyberg,et al.  Insulin-like Growth Factor II Plays a Central Role in Atherosclerosis in a Mouse Model* , 2002, The Journal of Biological Chemistry.

[47]  Alternative Transcript Analysis Methods for Exon Arrays , 2005 .

[48]  I. Konishi,et al.  Human ovarian surface epithelial (OSE) cells express LH/hCG receptors, and HCG inhibits apoptosis of OSE cells via up‐regulation of insulin‐like growth factor‐1 , 2001, International journal of cancer.

[49]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..

[50]  Xinglai Ji,et al.  Distinguishing between cancer driver and passenger gene alteration candidates via cross-species comparison: a pilot study , 2010, BMC Cancer.

[51]  S. Mok,et al.  PAX2 Expression in Low Malignant Potential Ovarian Tumors and Low-Grade Ovarian Serous Carcinomas , 2009, Modern Pathology.

[52]  S. Manna,et al.  Human Chorionic Gonadotropin Decreases Proliferation and Invasion of Breast Cancer MCF-7 Cells by Inhibiting NF-κB and AP-1 Activation* , 2004, Journal of Biological Chemistry.

[53]  Yan Xu,et al.  Lysophospholipids increase interleukin-8 expression in ovarian cancer cells. , 2001, Gynecologic oncology.

[54]  M. Winslet,et al.  Endothelin receptor antagonism and cancer , 2009, European journal of clinical investigation.

[55]  Eugene A. Kapp,et al.  Overview of the HUPO Plasma Proteome Project: Results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly‐available database , 2005, Proteomics.

[56]  M. Revelo,et al.  Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer. , 2006, Molecular endocrinology.

[57]  R. Borup,et al.  Differences in gene expression of granulosa cells from women undergoing controlled ovarian hyperstimulation with either recombinant follicle-stimulating hormone or highly purified human menopausal gonadotropin. , 2009, Fertility and sterility.

[58]  A. Venn,et al.  Risk of cancer after use of fertility drugs with in-vitro fertilisation , 1999, The Lancet.

[59]  E. Berns,et al.  Luteinizing hormone signaling and breast cancer: polymorphisms and age of onset. , 2003, The Journal of clinical endocrinology and metabolism.

[60]  A. Amsterdam,et al.  Ovarian transcriptomes as a tool for a global approach of genes modulated by gonadotropic hormones in human ovarian granulosa cells. , 2005, Endocrine.

[61]  C. Brekelmans.  Risk factors and risk reduction of breast and ovarian cancer , 2003, Current opinion in obstetrics & gynecology.

[62]  P. Dickman,et al.  Ovarian epithelial neoplasia after hormonal infertility treatment: long-term follow-up of a historical cohort in Sweden. , 2009, Fertility and sterility.

[63]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[64]  J Halpern,et al.  Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. I. Methods. Collaborative Ovarian Cancer Group. , 1992, American journal of epidemiology.